Fundz

Lian Bio reported raising $270 Million in an initial SEC Form D filing, from an offering of $310 Million

PUBLIC · LIANYNov 12, 2020$270M of $310M raised

Amount Raised

$270 Million

$270 Million sold, per SEC Form D (first sale Nov 12, 2020)

Round Type

Venture

PrincetonBiotechnologyHealthcareHealth Care

Who else raised in Healthcare and Biotechnology around the same time

Companies in the same sectors as LianBio that raised within 45 days of this round, from Fundz verified event records.

  • Definium Therapeutics raised $78K (Seed) on December 22, 2020.
  • OnKure Therapeutics, Inc. raised $47M on December 21, 2020.
  • ReAlta Life Sciences raised $23M on December 18, 2020.
  • TuHURA Biosciences raised $2.7M (Seed) on December 17, 2020.
  • CytoDyn raised $1M (Seed) on December 16, 2020.
  • CytoDyn raised an undisclosed amount on December 16, 2020.

Who to call at LianBio, and when

A new round usually means LianBio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day LianBio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at LianBio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at LianBio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

LianBio

Location

C/O OGIER GLOBAL (CAYMAN) LIMITED

Princeton, New Jersey, United States

About

LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets. For additional information, please visit the company’s website at www.lianbio.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment LianBio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for LianBio's next move

See what Strategic adds

LianBio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.